Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis

doi:10.1183/23120541.00356-2023

. 2023 Aug 29;9(4):00356-2023.

doi: 10.1183/23120541.00356-2023. eCollection 2023 Jul.

Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis

Jessica Rademacher^{1

2}, Luise Martin^{3

4

5}, Anja Theloe⁶, Mirjam Stahl^{3

4

5}, Marcus A Mall^{3

4

5}, Oana Joean¹, Jan Fuge^{1

2}, Gesine Hansen^{2

7}, Tobias Welte^{1

2}, Katharina Schütz⁷, Felix C Ringshausen^{1

2

8

9}, Anna M Dittrich^{2

7

9}

Affiliations

¹ Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
² Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
³ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
⁴ DZL, associated partner site, Berlin, Germany.
⁵ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁶ Pharmacy Department, Charité - Universitätsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
⁷ Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
⁸ European Reference Network on Rare and Complex Respiratory Diseases (ERN-LUNG), Frankfurt, Germany.
⁹ These authors contributed equally.

PMID: 37650087
PMCID: PMC10463032
DOI: 10.1183/23120541.00356-2023

Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis

Jessica Rademacher et al. ERJ Open Res. 2023.

. 2023 Aug 29;9(4):00356-2023.

doi: 10.1183/23120541.00356-2023. eCollection 2023 Jul.

Authors

Affiliations

¹ Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.
² Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany.
³ Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
⁴ DZL, associated partner site, Berlin, Germany.
⁵ Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁶ Pharmacy Department, Charité - Universitätsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
⁷ Department of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
⁸ European Reference Network on Rare and Complex Respiratory Diseases (ERN-LUNG), Frankfurt, Germany.
⁹ These authors contributed equally.

PMID: 37650087
PMCID: PMC10463032
DOI: 10.1183/23120541.00356-2023

Abstract

AMS in chronic lung disease can be challenging. Causal treatment of treatable traits may be the most successful AMS strategy for patients with any chronic pulmonary disease and should be brought into focus. https://bit.ly/3ptrmV8.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

**FIGURE 1**
a and b) Antibiotic consumption in recommended daily doses (RDDs) per 100 patient-days; c and d) patient occupancy from 2017 to 2021.

See this image and copyright information in PMC

References

1. Principi N, Esposito S. Antimicrobial stewardship in paediatrics. BMC Infect Dis 2016; 16: 424. doi:10.1186/s12879-016-1772-z - DOI - PMC - PubMed
1. Nhan D, Lentz EJM, Steinberg M, et al. . Structure of antimicrobial stewardship programs in leading US hospitals: findings of a nationwide survey. Open Forum Infect Dis 2019; 6: ofz104. doi:10.1093/ofid/ofz104 - DOI - PMC - PubMed
1. Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr Opin Infect Dis 2011; 24: Suppl. 1, S11–S20. doi:10.1097/01.qco.0000393484.17894.05 - DOI - PubMed
1. Darboe S, Mirasol R, Adejuyigbe B, et al. . Using an antibiogram profile to improve infection control and rational antimicrobial therapy in an urban hospital in the Gambia, strategies and lessons for low- and middle-income countries. Antibiot Basel Switz 2023; 12: 790. - PMC - PubMed
1. Bell SC, Mall MA, Gutierrez H, et al. . The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020; 8: 65–124. doi:10.1016/S2213-2600(19)30337-6 - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central

[1] Principi N, Esposito S. Antimicrobial stewardship in paediatrics. BMC Infect Dis 2016; 16: 424. doi:10.1186/s12879-016-1772-z - DOI - PMC - PubMed

[2] Principi N, Esposito S. Antimicrobial stewardship in paediatrics. BMC Infect Dis 2016; 16: 424. doi:10.1186/s12879-016-1772-z - DOI - PMC - PubMed

[3] Nhan D, Lentz EJM, Steinberg M, et al. . Structure of antimicrobial stewardship programs in leading US hospitals: findings of a nationwide survey. Open Forum Infect Dis 2019; 6: ofz104. doi:10.1093/ofid/ofz104 - DOI - PMC - PubMed

[4] Nhan D, Lentz EJM, Steinberg M, et al. . Structure of antimicrobial stewardship programs in leading US hospitals: findings of a nationwide survey. Open Forum Infect Dis 2019; 6: ofz104. doi:10.1093/ofid/ofz104 - DOI - PMC - PubMed

[5] Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr Opin Infect Dis 2011; 24: Suppl. 1, S11–S20. doi:10.1097/01.qco.0000393484.17894.05 - DOI - PubMed

[6] Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr Opin Infect Dis 2011; 24: Suppl. 1, S11–S20. doi:10.1097/01.qco.0000393484.17894.05 - DOI - PubMed

[7] Darboe S, Mirasol R, Adejuyigbe B, et al. . Using an antibiogram profile to improve infection control and rational antimicrobial therapy in an urban hospital in the Gambia, strategies and lessons for low- and middle-income countries. Antibiot Basel Switz 2023; 12: 790. - PMC - PubMed

[8] Darboe S, Mirasol R, Adejuyigbe B, et al. . Using an antibiogram profile to improve infection control and rational antimicrobial therapy in an urban hospital in the Gambia, strategies and lessons for low- and middle-income countries. Antibiot Basel Switz 2023; 12: 790. - PMC - PubMed

[9] Bell SC, Mall MA, Gutierrez H, et al. . The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020; 8: 65–124. doi:10.1016/S2213-2600(19)30337-6 - DOI - PMC - PubMed

[10] Bell SC, Mall MA, Gutierrez H, et al. . The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020; 8: 65–124. doi:10.1016/S2213-2600(19)30337-6 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis

Affiliations

Optimal treatment of the underlying aetiology is the most effective antimicrobial stewardship for chronic respiratory disease: a lesson learned from cystic fibrosis

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

References

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

References

Related information

LinkOut - more resources

Full Text Sources